BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 28366014)

  • 1. Promising immunotherapies for esophageal cancer.
    Tanaka T; Nakamura J; Noshiro H
    Expert Opin Biol Ther; 2017 Jun; 17(6):723-733. PubMed ID: 28366014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for esophageal squamous cell carcinoma: a review.
    Mimura K; Yamada L; Ujiie D; Hayase S; Tada T; Hanayama H; Thar Min AK; Shibata M; Momma T; Saze Z; Ohki S; Kono K
    Fukushima J Med Sci; 2018 Aug; 64(2):46-53. PubMed ID: 30058598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for the treatment of breast cancer.
    Moreno Ayala MA; Gottardo MF; Asad AS; Zuccato C; Nicola A; Seilicovich A; Candolfi M
    Expert Opin Biol Ther; 2017 Jul; 17(7):797-812. PubMed ID: 28446053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.
    Tran E; Robbins PF; Rosenberg SA
    Nat Immunol; 2017 Feb; 18(3):255-262. PubMed ID: 28198830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for head and neck cancer: the future of treatment?
    Xie X; O'Neill W; Pan Q
    Expert Opin Biol Ther; 2017 Jun; 17(6):701-708. PubMed ID: 28368668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
    Kyi C; Postow MA
    Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors: a new era for esophageal cancer.
    Zou LQ; Yang X; Li YD; Zhu ZF
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):731-738. PubMed ID: 31424306
    [No Abstract]   [Full Text] [Related]  

  • 13. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Approaches for Immune Directed Treatment for Ovarian Cancer.
    Hardwick N; Frankel PH; Cristea M
    Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New checkpoints in cancer immunotherapy.
    Ni L; Dong C
    Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the immune system to treat lung cancer: rationale and clinical experience.
    Guibert N; Delaunay M; Mazières J
    Ther Adv Respir Dis; 2015 Jun; 9(3):105-20. PubMed ID: 25827132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
    Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
    Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.